Search results
Results from the WOW.Com Content Network
Acute effects while under the influence can sometimes include euphoria or anxiety. [4] [5] Although some assert that cannabidiol (CBD), another cannabinoid found in cannabis in varying amounts, may alleviate the adverse effects of THC that some users experience, [6] little is known about CBD's effects on humans.
the negative effect on intelligence is greater than that attributable to the lack of education. ceasing consumption does not fully restore cognitive function on adolescents. [16] Cannabis. Cannabis intoxication was not only found to affect attention, psychomotor task ability, and short-term memory.
Abnormal cannabidiol (Abn-CBD) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive or sedative effects.
[4] [19] CBD does not have the same psychoactivity as THC, [24] [25] and can modulate the psychoactive effects of THC on the body if both are present. [16] [24] [26] [27] Conversion of CBD to THC can occur when CBD is heated to temperatures between 250–300 °C, potentially leading to its partial transformation into THC. [28]
Corticobasal degeneration (CBD) is a rare neurodegenerative disease involving the cerebral cortex and the basal ganglia. [1] CBD symptoms typically begin in people from 50 to 70 years of age, and typical survival before death is eight years.
In a study from 2019, salicylic acid (SA) was used with GABA as an elicitor to determine its effects on the expression of metabolites involved in THC and CBD biosynthesis. SA and GABA were demonstrated to effectively up-regulate the expression of THCAS , a cannabigerolic acid used to form THC, which resulted in higher levels of THC. [ 19 ]
Cannabinoid receptor 1 (CB1), is a G protein-coupled cannabinoid receptor that in humans is encoded by the CNR1 gene. [5] And discovered, by determination and characterization in 1988, [6] and cloned in 1990 for the first time.
While the most likely cellular targets and executors of the CB 2 receptor-mediated effects of endocannabinoids or synthetic agonists are the immune and immune-derived cells (e.g. leukocytes, various populations of T and B lymphocytes, monocytes/macrophages, dendritic cells, mast cells, microglia in the brain, Kupffer cells in the liver ...